# Amneal Pharmaceuticals Inc. (AMRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $4.98B  
**Price:** $15.32 (+4.29%)

> Amneal Pharmaceuticals Inc. is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of essential medicines across three reportable segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers a broad range of generic pharmaceuticals in various dosage forms and delivery systems, including complex injectables, biosimilars like denosumab referencing Prolia and XGEVA, respiratory therapies such as albuterol sulfate inhalation aerosol equivalent to PROAIR HFA, ophthalmic products like cyclosporine emulsion equivalent to RESTASIS, and iohexol injection as the first generic of Omnipaque. The Specialty segment focuses on proprietary branded pharmaceuticals targeting central nervous system disorders, such as CREXONT for Parkinson’s disease to improve motor symptom control, and endocrine therapies like UNITHROID. The AvKARE segment supplies pharmaceuticals and medical products to governmental agencies through re-packaging and wholesale distribution, emphasizing consistent care and pricing. Operating in the U.S., India, and Ireland, Amneal Pharmaceuticals Inc. supports healthcare providers, institutions, and patients with affordable and innovative treatments. Founded in 2002 and headquartered in Bridgewater, New Jersey, it plays a key role in the generics, specialty, and institutional pharmaceuticals markets.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3.02B | $1.11B | $394M | $72M | — |
| 2024 | $2.79B | $1.02B | $249M | -$117M | — |
| 2023 | $2.39B | $821M | $204M | -$84M | — |
| 2022 | $2.21B | $785M | -$95M | -$271M | — |
| 2021 | $2.09B | $769M | $153M | $13M | — |
| 2020 | $1.99B | $628M | $91M | $68M | — |
| 2019 | $1.63B | $353M | -$249M | -$604M | — |
| 2018 | $1.66B | $716M | -$20M | -$20M | — |
| 2017 | $1.03B | $526M | $245M | — | — |
| 2016 | $1.02B | $597M | $285M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3.68B | $3.75B | -$71M | $282M | $2.57B |
| 2024 | $3.50B | $3.61B | -$109M | $111M | $2.39B |
| 2023 | $3.47B | $3.45B | $20M | $92M | $2.42B |
| 2022 | $3.80B | $3.50B | $298M | $26M | $2.62B |
| 2021 | $3.94B | $3.58B | $360M | $248M | $2.71B |
| 2020 | $4.01B | $3.70B | $303M | $341M | $2.78B |
| 2019 | $3.67B | $3.43B | $232M | $151M | $2.63B |
| 2018 | $4.35B | $3.85B | $505M | $213M | $2.65B |
| 2017 | $1.34B | — | — | $74M | $1.44B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $340M | $70M | $270M |
| 2024 | $295M | $52M | $243M |
| 2023 | $346M | $43M | $302M |
| 2022 | $65M | $46M | $19M |
| 2021 | $242M | $48M | $194M |
| 2020 | $379M | $56M | $323M |
| 2019 | $2M | $47M | -$45M |
| 2018 | $250M | $83M | $167M |
| 2017 | $234M | $95M | $139M |
| 2016 | $115M | $123M | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AMRX)